Literature DB >> 10085398

Total esophagectomy versus proximal esophagectomy for esophageal cancer at the cervicothoracic junction.

H Fujita1, T Kakegawa, H Yamana, S Sueyoshi, S Hikita, T Mine, Y Tanaka, H Ishikawa, K Shirouzu, K Mori, Y Inoue, H Y Tanabe, K Kiyokawa, Y Tai, H Inutsuka.   

Abstract

To investigate the adequate extent of esophagectomy and lymphadenectomy for an esophageal cancer localized at the cervicothoracic junction, the mortality and morbidity rates, survival rates, and patterns of recurrence were retrospectively analyzed in two groups-14 patients who underwent total esophagectomy with or without laryngectomy and 15 patients who underwent proximal esophagectomy with or without laryngectomy-at Kurume University Hospital from 1981 to 1996. Proximal esophagectomy with or without laryngectomy resulted in a lower hospital mortality rate and better overall survival for patients who underwent curative esophagectomy compared with total esophagectomy with or without laryngectomy. Multivariate analysis indicated that the extent of esophagectomy (total esophagectomy versus proximal esophagectomy) was not a prognostic factor. The incidence of recurrence was not different between the two groups. Lymph node metastasis or recurrence from such esophageal cancers was localized to the neck and upper mediastinum. For an esophageal cancer localized at the cervicothoracic junction, therefore, proximal esophagectomy with or without laryngectomy and with cervical and upper mediastinal lymphadenectomy could be better indicated for preselected patients.

Entities:  

Mesh:

Year:  1999        PMID: 10085398     DOI: 10.1007/pl00012336

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  1 in total

1.  Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction.

Authors:  Peter Panhofer; Christopher Springer; Barbara Izay; Matthäus Grasl; Martin Burian; Sebastian F Schoppmann; Thomas Rath; Raimund Jakesz; Johannes Zacherl
Journal:  Langenbecks Arch Surg       Date:  2012-09-02       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.